These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 28919987)
1. Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study. Mletzko S; Pinato DJ; Robey RC; Dalla Pria A; Benson P; Imami N; Bower M Oncoimmunology; 2017; 6(8):e1304337. PubMed ID: 28919987 [TBL] [Abstract][Full Text] [Related]
2. Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. Host KM; Jacobs SR; West JA; Zhang Z; Costantini LM; Stopford CM; Dittmer DP; Damania B mBio; 2017 Oct; 8(5):. PubMed ID: 29018115 [TBL] [Abstract][Full Text] [Related]
3. Expression of Programmed Cell Death Proteins in Kaposi Sarcoma and Cutaneous Angiosarcoma. Gambichler T; Koim S; Wrobel M; Käfferlein HU; Brüning T; Stockfleth E; Becker JC; Lang K J Immunother; 2020 Jun; 43(5):169-174. PubMed ID: 32224717 [TBL] [Abstract][Full Text] [Related]
4. Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation. Chen J; Del Valle L; Lin HY; Plaisance-Bonstaff K; Forrest JC; Post SR; Qin Z Virology; 2019 Oct; 536():16-19. PubMed ID: 31394407 [TBL] [Abstract][Full Text] [Related]
5. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma. Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366 [TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. Spurny C; Kailayangiri S; Jamitzky S; Altvater B; Wardelmann E; Dirksen U; Hardes J; Hartmann W; Rossig C Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28868758 [TBL] [Abstract][Full Text] [Related]
7. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells. Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303 [TBL] [Abstract][Full Text] [Related]
8. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1. Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721 [TBL] [Abstract][Full Text] [Related]
9. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer. Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649 [TBL] [Abstract][Full Text] [Related]
10. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404 [TBL] [Abstract][Full Text] [Related]
11. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells. Gibbons Johnson RM; Dong H Front Immunol; 2017; 8():961. PubMed ID: 28848559 [TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8 Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272 [TBL] [Abstract][Full Text] [Related]
15. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. Wang S; Liechty B; Patel S; Weber JS; Hollmann TJ; Snuderl M; Karajannis MA J Neurooncol; 2018 May; 138(1):183-190. PubMed ID: 29427150 [TBL] [Abstract][Full Text] [Related]
16. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503 [TBL] [Abstract][Full Text] [Related]
17. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer. Drakes ML; Mehrotra S; Aldulescu M; Potkul RK; Liu Y; Grisoli A; Joyce C; O'Brien TE; Stack MS; Stiff PJ J Ovarian Res; 2018 May; 11(1):43. PubMed ID: 29843813 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. D'Angelo SP; Shoushtari AN; Agaram NP; Kuk D; Qin LX; Carvajal RD; Dickson MA; Gounder M; Keohan ML; Schwartz GK; Tap WD Hum Pathol; 2015 Mar; 46(3):357-65. PubMed ID: 25540867 [TBL] [Abstract][Full Text] [Related]
20. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Wang B; Pan W; Yang M; Yang W; He W; Chen X; Bi J; Jiang N; Huang J; Lin T Cancer Sci; 2019 Feb; 110(2):489-498. PubMed ID: 30548363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]